These findings highlight therapeutic opportunities for side-specific CRC treatment, including hypoxia targeting in RCRC, MMP7+ cancer cell targeting in advanced LCRC, and the potential disruption of immunosuppressive, angiogenic, and migratory axes. This evidence concerns the gene MMP7 and cancer.